In its largest investment to date in the healthy aging sector, Noom, the Princeton-based behavior change company, announced it has finalized the acquisition of Tailor Made Compounding (TMC). TMC is a licensed 503A compounding pharmacy operating across 46 states, including California.
The acquisition marks a strategic pivot for Noom, signaling its intent to expand its range of clinically appropriate therapies and treat conditions well beyond its traditional focus on weight health.
By bringing TMC’s capabilities in-house, Noom aims to pair its highly engaged digital behavior-change platform with prescription-grade catalysts to drive sustainable, long-term health outcomes.
“Weight health is the entry point to preventive care – and foundational to healthy aging,” Geoff Cook, CEO of Noom said. “But it’s not the end point. This acquisition continues Noom’s expansion into healthy aging, supporting Noom’s mission to empower everyone, everywhere to live better longer – every day.”
Cook noted that the company plans to broaden its formulary to include peptide-based therapies, such as sermorelin, and other healthy aging interventions like NAD+, as they actively push into new medical conditions.
Tailor Made Compounding provides both sterile and non-sterile compounding services. Its diverse formulary covers several critical wellness areas:
- Men’s and women’s health
- Weight management and healthy aging
- Specialized supplements and IV therapy
- Advanced cosmetics
TMC currently serves over 400 clinics and various telehealth partners. Moving forward, TMC will continue to operate as a wholly owned subsidiary under its current leadership team, including CEO Ross Jordan, ensuring that its existing client base still has access to its broad formulary of health solutions.
The acquisition follows a massive physical expansion by TMC in 2024. The company completed a 22,000-square-foot expansion of its state-of-the-art compounding facility, bringing its total footprint to more than 40,000 square feet. This facility features advanced environmental controls and barcoded inventory systems, positioning it perfectly to scale alongside Noom’s massive digital footprint.
“By joining Noom, we can integrate those therapies into a proven behavior-change platform focused on long-term outcomes,” Ross Jordan, CEO of Tailor Made Compounding said. “With medicine and habit science working together, we can support a healthcare ecosystem built for individualized care and lasting outcomes.”
Noom expects to fully integrate TMC and launch its new health aging initiatives later this summer.
